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direct variable costs, in addition to total ICU costs, is needed to understand short-term and long-term impact
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Evaluating the Economic Impact of Palliative
and End-of-Life Care Interventions on Intensive Care Unit
Utilization and Costs from the Hospital
and Healthcare System Perspective
Nita Khandelwal, MD, MS,1 Lyndia C. Brumback, PhD,2 Scott D. Halpern, MD, PhD, MBE,3
Norma B. Coe, PhD,4 Babette Brumback, PhD,5 and J. Randall Curtis, MD, MPH6
Abstract
Purpose of report: Understanding the impact of palliative care interventions on intensive care unit (ICU) costs
and utilization is critical for demonstrating the value of palliative care. Performing these economic assessments,
however, can be challenging. The purpose of this special report is to highlight and discuss important consid-
erations when assessing ICU utilization and costs from the hospital perspective, with the goal of providing
recommendations on methods to consider for future analyses.
Findings: ICU length of stay (LOS) and associated costs of care are common and important outcome measures,
but must be analyzed properly to yield valid conclusions. There is significant variation in costs by day of stay in
the ICU with only modest differences between an ICU day at the end of a stay and the first day on the acute care
floor; this variation must be appropriately accounted for analytically. Furthermore, reporting direct variable
costs, in addition to total ICU costs, is needed to understand short-term and long-term impact of a reduction in
LOS. Importantly, incentives for the hospital to realize savings vary depending on reimbursement policies.
Summary: ICU utilization and costs are common outcomes in studies evaluating palliative care interventions.
Accurate estimation and interpretation are key to understanding the economic implications of palliative care
interventions.
Keywords: critical care; economics; ICU costs; palliative care
Introduction
In the United States, critical care costs are estimated toexceed $82 billion annually, accounting for 13% of inpa-
tient hospital costs and 0.7% of the Gross Domestic Pro-
duct.1,2 Although the number of hospital beds in the United
States has decreased over the past decade, the number of ICU
beds has increased.3 Consequently, interventions that target
reducing costs in the ICU are of great interest.
While the primary goal of palliative and end-of-life care
interventions is to improve the quality of care for seriously ill
and dying patients, there is evidence to suggest that these
interventions can simultaneously reduce nonbeneficial ICU
utilization.4 Understanding and evaluating the impact of
these interventions on ICU costs has important implications
for hospitals and healthcare systems that must operate in a
resource-limited setting. Robust economic evaluations are
needed to help payers and policy makers guide resource al-
location5,6 and decide the utility of investing in palliative and
end-of-life care programs.
Conducting these evaluations in the ICU setting, however,
can be challenging for a variety of reasons andmay be fraught
with common errors.7,8 Our objective is to discuss important
considerations when assessing the economic impact of these
interventions on ICU resources, with the goal of providing
recommendations on methods to consider for future analyses.
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Specifically, we will address: (1) length of stay (LOS) as an
outcomemeasure; (2) complexities of costs and time horizon;
and (3) economic evaluations from the hospital and health-
care system perspective under different payment models.
This information is important for palliative care and ICU
clinicians interested in making an economic case for the
value of palliative care before and in the ICU.
Length of Stay as an Outcome Measure
LOS in the ICU is one of the most common outcome
measures reported in studies evaluating palliative care inter-
ventions.9–25 This is not surprising as it is an outcome of in-
terest for patients, families, clinicians, and healthcare systems.
Long ICU stays are costly to hospitals, payers, and society and
more importantly, are associated with symptoms of pain,
stress, and anxiety for patients and families.26 Unlike many
important outcomes of palliative care interventions, such as
quality of life and quality of dying, it is also relatively easy to
measure. However, this ease of measurement also creates
opportunity for varied and errant measurement and analysis.
Several randomized trials evaluating palliative and end-of-
life care interventions aimed at improving communication
between patients, families, and medical teams have observed
shorter mean LOS for ICU decedents in the intervention arm
compared with the control arm.9,10,15,27 In each of these trials,
the investigators did not detect a difference in mean LOS be-
tween treatment arms for ICU survivors, nor did they detect a
difference in the proportion who died in the ICU between
intervention and control patients. It is therefore tempting to
conclude that the primary mechanism for reducing LOS with
palliative and end-of-life care interventions is earlier with-
drawal of life-sustaining treatments in patients who are going
to die. However, caution is needed when interpreting results
from analyses that stratify on a variable (death in the ICU) that
can only be known after randomization, and hence could be
influenced by the intervention.28 Thus, outcome-based sub-
sample analyses, or analyses that stratify on events occurring
after randomization, may yield biased results.29
Although it may be useful to demonstrate the very real
possibility that a palliative care intervention’s primary effect
may be to shorten LOS among patients who will die in the
ICU with or without the intervention, such analyses are most
valid if the intervention’s effect on mortality is truly null (i.e.,
a mortality effect of 0 with a very narrow confidence inter-
val). This is a standard that will rarely be met given the
modest sample sizes of most ICU-based palliative care trials.
Nonetheless, this may be a valuable analysis, provided
mortality in the ICU and overall are equivalent in the two
treatment arms; however, demonstrating equivalence in this
setting may be especially challenging.
An alternate approach to stratifying on death in the ICU is
to apply standard survival analysis methods, such as Kaplan–
Meier estimates, log rank tests, and Cox proportional hazards
regression models. However, in many cases, these analyses
ignore death, leading to uncertainty regarding whether the
effect of a palliative or end-of-life care intervention on LOS
was attributable to shortening the time to death, increasing
the number of deaths, or reducing LOS among survivors.
Some investigators censor LOS at the time of death for those
who die in the ICU. However, for such approaches to yield
interpretable results requires that censoring is not informa-
tive.30 This is a problematic assumption, as patients’ acuities
and comorbid conditions are related to both their probability
of dying and their LOS if they survive. Thus, the probability
of censoring may be time dependent, and thus introduce bias
even in randomized trials.31
A third approach to analyzing ICULOS in studies of palliative
care or similar interventions is to create a new outcome variable
that takes the value of the observed LOS for those who leave
the ICU alive and some prespecified value for those who die
in the ICU. For example, the value for those who die in the ICU
could be specified as the longest observed LOS (worst outcome),
or some long but submaximal LOS, thereby accounting for the
possibility that extremely long ICU LOS may be considered
by some patients to be a fate worse than death. Nonparametric
methods, such as Wilcoxon–Mann–Whitney tests, may then
be used to compare the distributions of LOS outcomes under
treatment and control because the exact numerical value of the
new variable for those who died in the ICU does not matter, only
its rank or ‘‘placement’’ in the observed data matters. As noted
by Lin et al.,30 this approach does not violate any of the statistical
assumptions embedded in other analytic approaches. This ap-
proach should be specified a priori in studies employing it, and
ideally would quantify the range of LOS values that death could
assume based on studies of patients’ preferences because the
‘‘right’’ ranking of death depends on how patients value the
avoidance of long ICU LOS relative to death.
Alternatively, investigators can propose to ‘‘place’’ death in
the ICU at a range of values on the LOS distribution and
evaluate the degree to which the conclusions are sensitive to
this ranking. Thus, although it may be unknowable how certain
patients value long ICU lengths of stay relative to death, in-
vestigators can specify the range of such potential valuations
over which the conclusions of the primary analysis would still
apply. Because palliative care interventions are more likely to
be beneficial by reducing lengths of stay than by saving lives,
the sensitivity of the results to where death in the ICU is ranked
on the LOS distribution is likely to be small. However, if a
palliative care intervention were to increase ICU mortality,
then appropriately accounting for preferences between long
ICU stays and death will be essential.
A potential problem with each of these approaches is that
deaths outside of the ICU are not accounted for. For example,
consider a randomized trial comparing a palliative care in-
tervention with usual care. Patients in the intervention group
may leave the ICU sooner, and more commonly leave the
ICU alive, if the intervention encourages earlier adoption of
hospice care. Although this might be a beneficial effect from
patients’ perspectives, it would be wrong to conclude—as the
foregoing approaches might—that the intervention saved
lives. Its benefit would be in changing the circumstances,
location, and nature of dying.
This highlights the potential value of studies in which
patients can be followed for some time after leaving the ICU
alive. In such cases, analyses that model the time alive and
not in the ICU for some prespecified time after randomization
(i.e., 28 or 60 days) become possible. This approach is
analogous to outcomes such as ‘‘ventilator-free days’’32 or
‘‘ICU-free days’’.33 Greater values of this outcome (time
alive and not in ICU during some prespecified time after
randomization) are better. For example, a patient who left the
ICU after 3 days and was still alive 28 days after randomi-
zation would have an outcome of 25 days, a patient who left
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the ICU after 20 days and was still alive 28 days after ran-
domization would have an outcome of 8 days, a patient who
left the ICU after 3 days and died outside the ICU 11 days
after randomization would also have an outcome of 8 days,
and a patient in the ICU the entire prespecified time of
28 days and a patient who died in the ICU at any time within
28 days of randomization would both have an outcome of
0 days. This approach is simple and provides more infor-
mation about the effect of treatment on mortality. However,
by not distinguishing between patients who die in the ICU on
day 3 and patients who die in the ICU on day 28, these
approaches fail to account for the fact that patients may value
these outcomes quite differently. This is particularly impor-
tant with regard to palliative care interventions because such
interventions may work precisely by reducing duration of life
support for those who will die regardless, which could be
viewed by many patients, families, and society as beneficial.
In summary, LOS is an important but complicated outcome.
The best way to analyze LOS will depend on the proposed
mechanism of the intervention, the study population, and the
research question. Additional research is needed to explore the
pros and cons of the approaches we have described.
Variation in Cost by Day of Stay in the ICU
and Marginal Difference between ICU Days
and Acute Care Floor Days
For interventions that demonstrate a reduction in ICU LOS,
the cost implications are heavily contingent upon where in the
ICU stay the days are saved. This is because significant vari-
ability in cost exists by day of the stay in the ICU. By looking
at patterns of daily costs in the ICU, several studies have found
that costs are highest on admission day and then decline dra-
matically and stabilize after days 2–3.34–38 One study devel-
oped a weighted ICU day as a measure of resource utilization,
in which admission day was weighted 4· that of following
days.36 Another study found a similar pattern when looking at
patients who were ventilated for more than 48 hours.35 A
sample of over 650,000 seriously ill patients in the ICUs of
community hospitals also demonstrated this pattern of ad-
mission day being themost expensive with decreasing costs on
subsequent days and levels stabilizing after day 2.37
Interestingly, a recent study looking at patterns of costs
across various ICU settings found that higher day 1 costs were
not found in patients admitted to medical/nonsurgical ICUs.39
This suggests that careful examination of the patterns of daily
costs and where in the ICU stay days are being reduced is
needed. Simply documenting the reduction in ICU days does
not accurately reflect the degree of savings, especially since
days reduced are generally at the end of an ICU stay. Conse-
quently, multiplying the average cost of an ICU day by the
number of days saved will be misleading. Prior investigators
have excluded the costs of the first two ICU days as a con-
servative approach to calculating costs,40 although we do not
recommend this approach since these are important ICU days,
especially when the length of ICU stay is relatively short.
Many studies evaluating the effect of palliative care-type
interventions have noted a reduction in ICU LOS for dece-
dents.9,10,27 In this situation, cost shifting does not occur
since the decedent’s care is not transferred elsewhere. Con-
versely, for patients who survive to ICU discharge and are
transferred to the acute care floor (any non-ICU acute care
bed, including surgical, medical, obstetric, etc.), it is essential
that cost shifting be taken into consideration. For the hospital
perspective, assuming total hospital LOS is not affected by
earlier ICU discharge, this is addressed by using the marginal
difference between the last day in the ICU and the first day on
the acute care floor to accurately estimate savings attributable
to reducing ICU LOS.
On the other hand, if discharge from the ICU one day
earlier leads to a one day reduction in total hospital LOS, the
cost reduction would be the sum of the marginal difference
between the last day in the ICU and first day on the acute care
floor plus the cost of the final foregone floor day. As a result
of the variation in costs by day of stay in the ICU, replacing
ICU days later in the course of an ICU stay with acute care
floor days may not result in dramatic savings35 on a per-
patient basis in the short term.
As a result of this variation in cost by day of stay in the ICU
and the marginal difference between terminal ICU days and
acute care floor days, the most accurate way to estimate the
effect of palliative care interventions on ICU costs is to source
primary cost data as the outcome of interest, rather than cal-
culating costs through LOS effect estimates. Furthermore, ob-
taining a broader perspective that includes the post-ICU course
is important to capture the effect of cost shifting. If primary cost
data are not available, then factoring in the difference in costs
by day of stay is needed to prevent misleading results.
Breaking Down Costs from the Hospital Perspective
and Selecting a Time Horizon
The vast majority of studies reporting on hospital and ICU
costs use total costs as the outcome of interest.41 Demon-
strating reductions in total costs, however, can be misleading,
since not all types of costswill be affected in the samewaywith
an intervention. While terminology may differ based on the
costing system, there are generally three categories of cost to
account for—indirect costs, direct fixed costs, and direct var-
iable costs. Indirect costs represent costs that the hospital in-
curs irrespective of patient volume; examples include building
maintenance and administrative salaries that are apportioned to
all billing sectors of the hospital. Direct fixed costs represent
costs that the hospital incurs to have an ICU of a particular size
but are irrespective of ICU patient volume; examples can in-
clude staff salaries and equipment such as mechanical venti-
lators. Direct variable costs are costs that fluctuate with patient
volume, characteristics, and intensity of treatment; examples
include laboratories, supplies, and drugs.42
It is estimated that direct variable costs comprise roughly
20% of total ICU costs, with the remainder being direct fixed or
indirect costs.35,43,44 Thus, from the hospital perspective in the
short-term, under volume-based fee-for-service (FFS) reim-
bursement, open beds have complicated economic implications
because hospitals must continue to pay direct fixed and indirect
costs irrespective of occupancy. Consequently, reporting the
effect of interventions on ICU costs necessitates breaking down
the cost outcome by indirect, direct fixed, and direct variable
components. If investigators are unable to obtain primary cost
data broken down into components, at the very minimum, es-
timates based on the literature of ICU cost components and
discussion of the limitations in using total costs are warranted.
One of the reasons that breaking down costs into three
categories is important is to help understand the cost savings
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from the hospital perspective under different time horizon
assumptions. The time horizon over which the effect of an
intervention is being measured is an important factor for
understanding the scale of cost savings. For example, over a
short time horizon, changes in savings are likely to be most
accurately reflected as changes in direct variable costs as
these are costs that are sensitive to patient volume and in-
dividual patient characteristics such as severity of illness,
whereas direct fixed and indirect costs are paid irrespective of
patient volume and cannot be saved.
Conversely, over a very long time horizon, direct fixed
costs can contribute to cost savings. This is because over a
long enough time horizon, direct fixed costs—and potentially
even indirect costs—can become variable.8 For example,
nursing staffing comprises an estimated 40% of total ICU
costs45 and is considered a fixed cost to the hospital as salaries
are generally paid irrespective of patient volume. However,
over a long time horizon, interventions that reduce bed oc-
cupancy may result in bed closures and the number of ICU
nurses a hospital employs, leading to a reduction in direct
fixed costs. Alternatively, such interventions may also reduce
the rate of growth in ICU beds, which may also reduce
healthcare costs over the long time horizon. Thus, the degree
of cost savings realized in the ICU depends on the time ho-
rizon selected for the economic evaluation.
The Role of the Payment Model in Economic
Evaluations from the Hospital and Healthcare
System Perspective
Another reason to break costs into the three aforemen-
tioned categories is to understand the incentive hospitals and
healthcare systems face to realize cost saving. Hospitals in
the United States have traditionally been shielded from the
incentive to cut costs because of the prevalence of FFS, also
known as indemnity insurance plans, in the health insurance
arena. These plans reimburse hospitals for their volume of
services, regardless of their impact on patient outcomes. Thus,
hospitals only had a financial incentive to limit use of services
if the reimbursement amount was lower than the direct vari-
able cost.
Experts agree that the FFS system is, at least in part, re-
sponsible for the soaring healthcare costs in the United
States.46–49 Efforts are underway to change how providers are
paid, shifting the emphasis away from volume and toward
value. In 2012, almost noMedicare payments were attached to
value; under the Affordable Care Act,Medicare has planned to
shift 50% of its payments to such programs by 2018.50 While
the future of the ACA remains uncertain, the Medicare Access
and CHIP Reauthorization Act of 2015 (MACRA), is not.
MACRA ended the sustainable growth rate formula for phy-
sicians participating inMedicare Part B, and provides financial
incentives to enroll in one of two value-based payment plans
starting in 2017. The creation of Accountable Care Organi-
zations (ACOs), a new payment and delivery model in which
providers agree to collectively take responsibility for the
quality and total healthcare costs for a population of patients,
are one way in which healthcare systems are trying to improve
healthcare and lower costs. ACOs participating in the Medi-
care Shared Saving Program are able to retain 50–60% of
realized savings. More than 500ACOs are currently being
funded by the private, public, and combined sectors.51
Table 1 outlines the characteristics of the most popular
value-based reimbursement plans.
These alternative payment models have varying degrees of
financial incentive for hospitals to cut costs. Bundled payment
Table 1. Summary of Different Reimbursement Plans and Key Opportunities
for Palliative Care Interventions in the ICU
Reimbursement
systema Description
Opportunities for palliative care
from the hospital perspective
Fee-for-service Each service is paid for separately, and payment
depends on the quantity of services provided.
For example each office visit, laboratory test,
or procedure will be paid for separately.
Provided hospital costs are greater than
reimbursement, palliative care can have a
key role in reducing unwanted intensity of
care and corresponding costs.
Bundled payment Reimbursement is based on an episode of care.
The most common example of this is ‘‘global
surgery periods,’’ where reimbursement for a
particular surgery is bundled–including preop-
erative, operative, and the postoperative period.
Provided hospital costs are greater than
reimbursement, palliative care can have a
key role in reducing unwanted intensity of
care and corresponding costs.
Hospital value-based
purchasing
This program rewards acute care hospitals based
on quality of care provided. It factors in
adherence to best clinical practices and pa-
tients’ experiences of care during the admis-
sion. Incentive payments to hospitals are
determined by performance on selected quality
measures and improvements made in quality
measures.
Palliative care can have a key role in
improving the quality of care delivered.
Capitated payment Reimbursement based on payment per person,
rather than per service provided, irrespective of
actual utilization. In this model, each health
plan is paid a prospective capitation payment.
Palliative care can have an important role in
managing high-cost patients with serious
illness and multimorbidity.
aReference: https://www.cms.gov
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plans reimburse hospitals per episode of care, as opposed to
per-item treatment costs. The larger bundle of goods on which
hospitals are reimbursed make it more likely that the reim-
bursement is lower than the direct variable costs incurred with
ICU care, and ICU stays are not always part of the treatment
plan for the particular bundle. Under value-based purchasing,
hospitals are reimbursed much like in a bundled payment
plan, but face additional rewards or penalties tied to main-
taining or increasing quality of care. To the extent that lower
ICU usage and/or shorter ICU stays are included as quality
measures,52 hospitals have additional financial incentive to
adopt interventions that curb nonbeneficial ICU stays. Finally,
under capitated payment systems, hospitals or healthcare
systems are reimbursed per patient, regardless of utilization.
Hospitals under capitated systems have the strongest financial
incentive to minimize costs for a given quality, since their
income is predetermined by the number of covered lives. All
costs related to the provision of care for these individuals are
borne by the hospital or healthcare system. In other words,
these hospitals and healthcare systems are responsible for the
full marginal cost of all treatment decisions.
Reducing volume-based FFS reimbursement and increas-
ing value-based purchasing has important implications for
palliative care interventions in the ICU and elsewhere.53
These interventions have the potential to improve quality of
life and quality of dying for seriously ill patients, while si-
multaneously reducing unwanted or nonbeneficial aggres-
sive, costly care. Consequently, incentives for hospitals and
healthcare systems to expand these programs that can im-
prove quality and reduce costs are likely to increase as we
move toward value-based purchasing of healthcare.
Conclusion
Intensive care utilization at the end-of-life is increasing in
the United States, despite evidence suggesting that this type of
aggressive care is not consistent with values and preferences of
most patients during the terminal phase of illness.54 Palliative
care interventions improve communication between medical
teams, patients, and their families—helping to ensure that pa-
tients receive the care they want as they face serious illness. In
addition to improving quality of care, to understand the value of
palliative care, we must also understand the economic impact
of these interventions. Understanding and assessing the effect
on ICU utilization and costs from the hospital and healthcare
system perspectives, however, can be challenging.
In this article, we have highlighted some of these challenges
and recommendations to address these challenges (summary
provided in Table 2). In particular, the move away from
volume-based FFS reimbursement and toward value-based
purchasing has important implications for palliative care in-
terventions. These interventions have the potential to improve
quality of life and quality of dying for seriously ill patients,
while simultaneously reducing unwanted or nonbeneficial
costly care, both metrics which now are financially rewarded.
Consequently, hospitals and healthcare systems have increased
incentives to adopt new palliative care interventions and ex-
pand palliative care programs that improve quality and reduce
costs. This represents an opportunity for clinicians, researchers,
and administrators interested in improving palliative care in the
ICU. In an era focused on cost containment and transition from
FFS to the value-based reimbursement environment, robust
economic evaluations are needed to guide resource allocation.
Table 2. Summary of Challenges to Consider and Recommendations When Evaluating the Economic
Impact of Palliative and End-of-Life Care Interventions on ICU Costs and Utilization
Challenge to
consider Rationale Recommendations
ICU LOS as an out-
come measure
This outcome measure is often reported
stratified by death in the ICU, which is
determined after randomization. Stratify-
ing on a postrandomization variable may
introduce bias.
Consider alternate approaches such as
(a) creating a new outcome variable that takes the
value of the observed LOS for those who
leave the ICU alive and a prespecified value
for those who die in the ICU,
(b) modeling the time alive and not in the ICU for
some prespecified time after randomization
Variation in cost by day
of stay and marginal
difference between
ICU days and acute
care floor days
ICU costs are not the same on all days of a
stay. Using the average cost of an ICU day
and multiplying it by LOS does not
accurately reflect costs for a particular
number of days in the ICU.
1. Obtain primary cost/day if possible, rather than
calculating costs based on LOS.
2. If unable to obtain primary cost data, use
published estimates of variation in costs by day
of stay from the literature (37, 38, 40)
Breaking down costs
from hospital per-
spective
Reporting total cost savings does not accu-
rately reflect potential savings from the
hospital perspective
1. When able to obtain primary cost data, break
down reporting of costs into indirect, direct
fixed and direct variable components.
2. If unable to obtain components of costs,
consider using percentage estimates from the
literature as a discussion point (37, 40).
Selecting a time
horizon
Degree of potential savings depends on the
time horizon that is being considered.
1. When selecting a short time horizon, savings
should reflect direct variable costs.
2. When selecting a long time horizon, savings
can reflect both direct variable costs and
discussion of potential direct fixed costs than
can be saved.
LOS, Length of stay.
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